These results indicate that de novo NAD synthesis, if activated, compensates for NAMPT inhibition in SCLC, and suggest that this activity partially accounts for NAMPTi-resistance in some NSCLC cells. The gene discussed is NAMPT; the disease is non-small cell lung carcinoma.